The RCT-869 demonstrated a favorable safety profile for the investigational product. The most common AEs reported were mild and transient, including headache, nausea, and fatigue. The incidence of AEs was similar between the treatment and placebo groups, with no significant differences in the rates of serious AEs or AEs leading to treatment discontinuation.
The researchers conducted several subgroup analyses to explore the heterogeneity of treatment effects across different patient populations. These analyses revealed that the investigational product was effective across various subgroups, including patients with different disease severities, comorbidities, and concomitant medications. RCT-869-
While the RCT-869 provides valuable insights into the efficacy and safety of the investigational product, there are several limitations to consider. The study's follow-up period was relatively short, and longer-term data are needed to fully understand the durability of treatment effects. Additionally, the study did not include a comparator arm with an active treatment, which would have provided further context for the results. The RCT-869 demonstrated a favorable safety profile for